首页> 美国卫生研究院文献>Journal of Clinical Neurology (Seoul Korea) >Ultrasound Enhanced Thrombolysis: Applications in Acute Cerebral Ischemia
【2h】

Ultrasound Enhanced Thrombolysis: Applications in Acute Cerebral Ischemia

机译:超声增强溶栓:在急性脑缺血中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Intravenous tissue plasminogen activator (TPA) improves patient chances to recover from stroke by inducing mostly partial recanalization of large intracranial thrombi. TPA activity can be enhanced with ultrasound including 2 MHz transcranial Doppler (TCD). TCD identifies residual blood flow signals around thrombi, and, by delivering mechanical pressure waves, exposes more thrombus surface to circulating TPA. The international multi-center CLOTBUST trial showed that ultrasound enhances thrombolytic activity of a drug in humans thereby confirming multi-disciplinary experimental research conducted worldwide for the past 30 years.In the CLOTBUST trial, the dramatic clinical recovery from stroke coupled with complete recanalization within 2 hours after TPA bolus occurred in 25% of patients treated with TPA+TCD compared to 8% who received TPA alone (p=0.02). Complete clearance of a thrombus and dramatic recovery of brain functions during treatment are feasible goals for ultrasound-enhanced thrombolysis that can lead to sustained recovery. An early boost in brain perfusion seen in the Target CLOTBUST group resulted in a trend of 13% more patients achieving favorable outcome at 3 months, subject for a pivotal trial. However, different results were achieved in a small TRUMBI trial and another study that used Transcranial Color-Coded Duplex Sonography (TCCD). Adverse bio-effects of mid-KHz (300) ultrasound promote bleeding, including brain areas not-affected by ischemia while exposure to multi-frequency / multi-element duplex ultrasound resulted in a trend towards higher risk of hemorrhagic transformations.To further enhance the ability of TPA to break up thrombi, current ongoing clinical trials include phase II studies of a single beam 2 MHz TCD with perflutren-lipid microspheres. Enhancement of intra-arterial TPA delivery is being clinically tested with 1.7-2.1 MHz pulsed wave ultrasound (EKOS catheter). Multi-national dose escalation studies of microspheres and the development of an operator independent ultrasound device are underway.
机译:静脉内组织纤溶酶原激活剂(TPA)通过诱导大面积颅内血栓的大部分局部再通,提高了患者从中风中康复的机会。包括2 MHz经颅多普勒(TCD)的超声可以增强TPA活性。 TCD可识别血栓周围的残留血流信号,并通过传递机械压力波使更多的血栓表面暴露于循环的TPA。国际多中心CLOTBUST试验显示,超声增强了人类药物的溶栓活性,从而证实了过去30年来在世界范围内进行的多学科实验研究。在CLOTBUST试验中,卒中的临床显着恢复以及在2分钟内完全重新通气在接受TPA + TCD治疗的患者中,有25%的患者接受了TPA推注后的小时数,而仅接受TPA的患者为8%(p = 0.02)。超声治疗中溶栓的完全清除和脑功能的显着恢复是超声增强溶栓的可行目标,可导致持续恢复。在Tar​​get CLOTBUST组中,脑灌注的早期增强导致在3个月内获得有利结果的患者增加了13%,这是一项关键性试验的对象。但是,在一个小型的TRUMBI试验和另一项使用经颅彩色编码双工超声(TCCD)的研究中,获得了不同的结果。中频(300)超声的不良生物效应会促进出血,包括不受缺血影响的脑部区域,而暴露于多频/多元素双工超声导致出血转化风险更高的趋势。具有TPA分解血栓的能力,当前正在进行的临床试验包括带有全氟哌啶脂微球的单束2 MHz TCD的II期研究。目前正在使用1.7-2.1 MHz脉冲波超声(EKOS导管)对动脉内TPA递送的增强进行测试。微球的多国剂量递增研究以及独立于操作人员的超声设备的开发正在进行中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号